The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Faulding, Mylan Laboratories
Approval Status: Approved July 1997
Treatment for: chronic occlusive arterial disease
General Information
Pentoxifylline is a 400 mg extended release tablet and the generic equivalent of Trental. It is being marketed by Hoechst Marion Roussel. Pentoxifylline extended release tablets are indicated for the treatment of leg pain caused chronic occlusive arterial disease of the limbs. Patient walking distance and daily activities are limited by the disease. Both Faulding and Mylan are now manufacturing Pentoxifylline.
Clinical Results
In a comparison between aspirin and pentoxifylline in the elderly, the level of pain did not change significantly with either aspirin or pentoxifylline, but patient’s walking distance was extended with the pentoxifylline group.
Mechanism of Action
Pentoxifylline increases red blood cell flexibility and improves blood flow.
